Pharmaxis Appoints French Distributor for Aridol(TM)
11 March 2009 - 5:10PM
PR Newswire (US)
SYDNEY, March 11 /PRNewswire-Asia/ -- Pharmaxis
(ASX:PXS)(NASDAQ:PXSL) is pleased to announce that it has appointed
Praxis Pharmaceutical France SARL as its French marketer and
distributer for the asthma diagnostic tool, Aridol. Praxis
Pharmaceutical is a recently established company created to
introduce a portfolio of respiratory specialist products into the
French pharmaceutical market. Praxis will complete the
reimbursement application for Aridol in France and thereafter
market the product to hospital specialists. Dr Alan Robertson,
Pharmaxis CEO said "We are delighted to announce this agreement and
are looking forward to working with Praxis on developing the French
market for Aridol. Aridol is a precisely engineered test that we
believe will be an improvement on current practice. Aridol improves
the identification of bronchial hyperresponsiveness which is one of
the hallmarks of asthma." The total population affected by Asthma
in France is approximately 3.1 million. The French bronchial
challenge testing market is dominated by methacholine and more than
25,000 tests are conducted annually with little recent innovation
in the field. Aridol's ability to detect airway hyperresponsiveness
in poorly controlled asthmatics offers information to the
respiratory physician that has previously not been available.
Aridol is approved for sale in most major European countries,
Australia and Korea. Aridol has been included in the Global
Initiative for Asthma guidelines, and in the U.S. Asthma Management
Guidelines. It is one of the tests recommended by the World
Anti-Doping Agency, and other sports governing bodies to ensure
elite athletes who are asthmatic are properly diagnosed and
treated. Forward-Looking Statements The statements contained in
this media release that are not purely historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements in this media release include statements regarding our
expectations, beliefs, hopes, goals, intentions, initiatives or
strategies, including statements regarding the potential for Aridol
and/or Bronchitol. All forward-looking statements included in this
media release are based upon information available to us as of the
date hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information, future
events or otherwise. We can not guarantee that any product
candidate will receive FDA or other regulatory approval or that we
will seek any such approval. Factors that could cause or contribute
to such differences include, but are not limited to, factors
discussed in the "Risk Factors and Other Uncertainties" section of
our Form 20-F lodged with the U.S. Securities and Exchange
Commission. CONTACT: Alan Robertson -- Chief Executive Officer Tel:
+61-2-9454-7200 Email: RELEASED THROUGH: Australia: Felicity
Moffatt Tel: +61-418-677-701 Email: United States: Brandon Lewis,
Trout Group Tel: +1-646-378-2915 Email: DATASOURCE: Pharmaxis Ltd
CONTACT: Alan Robertson, Chief Executive Officer, +61-2-9454-7200,
or ; or RELEASED THROUGH: Australia: Felicity Moffatt,
+61-418-677-701, or ; or United States: Brandon Lewis of Trout
Group, +1-646-378-2915, or
Copyright
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ): 0 recent articles
More Pharmaxis Limited - Sponsored Adr (Australia) (MM) News Articles